Active, not recruitingPHASE1, PHASE2NCT03945318
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- BION-1301 Single Dose(drug)
- Enrollment
- 103 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2026
Study locations (16)
- Amicis Research Center, Northridge, California, United States
- Colorado Kidney Care, P.C., Denver, Colorado, United States
- Nephrology Associates of Central Florida, Orlando, Florida, United States
- Elixia Tampa, LLC, Tampa, Florida, United States
- New York Nephrology, Clifton Park, New York, United States
- Chris Sholer, P.C., Oklahoma City, Oklahoma, United States
- Liberty Research Center, Arlington, Texas, United States
- Liberty Research Center, Dallas, Texas, United States
- Prolato Clinical Research Center, Houston, Texas, United States
- Soon Chun Hyang University Hospital Cheonan, Cheonan, Chungcheongnam-do, South Korea
- Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, South Korea
- National Health Insurance Service Ilsan Hospital, Goyang-si, Gyeonggi-do, South Korea
- Hanyang University Guri Hostpital, Guri-si, Gyeonggi-do, South Korea
- Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea
- Liverpool University Hospital NHS Foundation Trust, Liverpool, England, United Kingdom
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03945318 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital